In today’s briefing:
- RenovoRx’s Differentiated Targeted Drug Delivery Platform Addresses Hypovascular Cancers
RenovoRx’s Differentiated Targeted Drug Delivery Platform Addresses Hypovascular Cancers
- Introducing the CEO. Shaun Bagai has spent his career in medtech, starting as an intern at TransVascular. Guided by the company’s CEO, he chose entrepreneurship over medical school to make a broader impact on patient care.
- Bagai stayed at TransVascular to manage clinical research and, following its acquisition by Medtronic (NYSE: MDT), gained firsthand experience in bringing medical devices to market.
- He later deepened his expertise in developing and commercializing disruptive technologies through roles at Ardian (also acquired by Medtronic) and HeartFlow (NASDAQ: HTFL). I
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
